• Pharmacodynamic response to antiplatelet medication is heterogeneous.
Essentials
• Pharmacodynamic response to antiplatelet medication is heterogeneous.
• Platelet reactivity to dual antiplatelet therapy was analyzed by three platelet function assays.
• The prevalence of high and low platelet reactivity differed significantly between assays.
• Future trials are needed to determine the best assay to analyze platelet function.
Summary. Background: High on-treatment platelet reactivity (HTPR) to antiplatelet medication leads to ischemic events, whereas low on-treatment platelet reactivity (LTPR) increases bleeding risk. However, various trials have failed to demonstrate superiority of tailored antiplatelet regimens (ARCTIC, ANTARCTIC, Trigger-PCI, and GRAVITAS). TROPICAL-ACS was the first study that demonstrated the benefit of tailoring antiplatelet medication according to platelet function analysis. A potential reason may be that different platelet function assays were used in these trials. 
Introduction
Dual antiplatelet therapy (DAPT) is indispensable in patients after acute myocardial infarction and in patients undergoing cardiac interventions. However, it is well known that there is substantial interindividual variability in the pharmacodynamic response to antiplatelet medication [1] [2] [3] [4] [5] . Furthermore, it has been shown that high ontreatment platelet reactivity (HTPR) is associated with ischemic events, and that low on-treatment platelet reactivity (LTPR) is associated with bleeding [6] . However, only one trial was able to demonstrate a benefit of tailoring the antiplatelet regimen according to platelet function analyses [7] . The reason for this is unclear. Possible reasons may be the assay used for the determination of antiplatelet effects.
Methods
We investigated platelet function in 23 patients receiving permanent aspirin and clopidogrel medication. All patients had undergone (> 1 month previously) percutaneous coronary intervention (PCI). We used three different platelet function assays -Multiplate-impedance aggregometry (MP), light-transmission aggregometry (LTA), and vasodilator-stimulated phosphoprotein phosphorylation assay (VASP) -as previously described [8] [9] [10] . For LTA, HTPR to DAPT was defined as a maximum of aggregation (MOA) of > 46%, and LTPR to DAPT was defined as an MOA of < 19%. For MP, HTPR was set at > 46 aggregation units (AU), and LTPR was set at < 19 AU. For VASP, a platelet reactivity index (PRI) of > 50 was defined as HTPR, and a PRI of < 16 was defined as LTPR [6] .
Results and discussion
Patients were aged 75 AE 10 years. Of the patients, 81% had arterial hypertension, 73% had hypercholesterolemia, and 31% had diabetes mellitus. According to Spearman's rho, there were only moderate correlations between the assays: LTA versus VASP, r s = 0.488, P = 0.018; LTA versus MP, r s = 0.562, P = 0.005; and VASP versus MP, r s = 0.562, P = 0.005.
With LTA, HTPR occurred in 57% of patients; with VASP, it occurred in 43% of patients; and with MP, it occurred in 13% of patients (P = 0.008). According to LTA, only 35% of patients were in the therapeutic window; according to VASP, 57% of patients were in the therapeutic window; and according to MP, 48% of patients were in the therapeutic window (P = 0.3). With LTA, LTPR occurred in 9% of patients; with VASP, it occurred in 0% of patients; and with MP, it occurred in 39% of patients (P < 0.001). Therefore, the prevalences of HTPR and LTPR differed significantly between assays. Remarkably, in 17% of patients, one assay showed HTPR whereas another showed LTPR (Fig. 1) .
The major finding of this study was that the results of different platelet function assays differ substantially. ANTARCTIC, another large trial, failed to demonstrate superiority of tailored antiplatelet therapy [11] . The results are in line with those of other clinical trials (ARC-TIC, GRAVITAS, and Trigger-PCI) [12] [13] [14] . However, in contrast to prior studies, ANTARCTIC investigated a high-risk population (elderly patients with acute coronary syndrome [ACS] undergoing urgent PCI). Accordingly, a more potent P2Y 12 inhibitor (prasugrel) was used predominantly. The results were astonishing, as it is known that HTPR is associated with ischemic events and LTPR is associated with bleeding [6] . After ANTARCTIC, platelet function testing to tailor antiplatelet medication was considered to be 'dead'. However, the recent TROPI-CAL-ACS trial demonstrated a benefit of platelet function testing in clinical decision-making [7] . Possible reasons may be the sophisticated study design, the intelligent choice of a net clinical primary endpoint, the noninferiority hypothesis, or the platelet function assay applied. TROPICAL-ACS was the first of the above-mentioned landmark trials in tailored antiplatelet therapy that chose MP for the evaluation of P2Y 12 inhibition. This was remarkable, as MP requires more laboratory expertise and is more time-consuming than other bedside assays. In the present study, we were able to demonstrate that the results of different assays differ substantially. It is completely unknown which assay 'is correct'. However, given the TROPICAL-ACS findings, MP could possibly be the best assay for tailoring antiplatelet medication at present. Nevertheless, more studies are needed to address the question of the optimal antiplatelet regimen in individualized medicine.
In the tailored antiplatelet regimen arm of TROPI-CAL-ACS, 60% of patients with ACS were treated 'only' with clopidogrel. Clopidogrel is substantially less expensive than the newer agents prasugrel or ticagrelor, which represent the first choice for ACS patients, according to (57) 8 (35) 13 (57) 11 (48) 9 (39) 0 (0) 2 (9) 10 (43) 3 ( current guidelines. Therefore, this new 'step-down' regimen may also significantly reduce healthcare costs. This study had several limitations. The sample size was small, so generalizability is limited. Additionally, an assay that is commonly used assay in large trials, i.e. VerifyNow, was not tested in this study.
Conclusion
The results of different platelet function assays differ substantially. Up to now, only TROPICAL-ACS has demonstrated a benefit of tailoring antiplatelet medication according to platelet function analysis. Therefore, the following are needed: (i) basic, translational and clinical studies to develop a pharmacodynamically specific, bedside assay for evaluating antiplatelet effects; and (ii) large-scale trials to demonstrate improved outcomes in terms of ischemic and bleeding events with tailored antiplatelet regimens. 
